On November 11, 2024, Judy Olian, a Director at United Therapeutics Corp (UTHR, Financial), sold 1,750 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 5,655 shares of United Therapeutics Corp.
United Therapeutics Corp, a biotechnology firm, focuses on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Over the past year, Judy Olian has sold a total of 18,450 shares of United Therapeutics Corp and has not purchased any shares. This recent transaction is part of a broader trend observed over the past year, where there have been no insider buys and 115 insider sells within the company.
Shares of United Therapeutics Corp were trading at $412.48 on the day of the sale. The company currently holds a market cap of $17.90 billion. The price-earnings ratio stands at 17.61, which is below the industry median of 26.75.
The stock's GF Value is calculated at $328.15, indicating that at a price of $412.48, United Therapeutics Corp is modestly overvalued with a price-to-GF-Value ratio of 1.26.
The GF Value is determined by considering historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This sale by the insider may be of interest to current and potential investors, providing insight into insider confidence and valuation perspectives at United Therapeutics Corp.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
